remain focu
ep beat revenu beat estim
mileston payment account half bottom line
beat top-line beat launch product
parsabiv repatha perform well management also offer solid
updat reimburs aimovig repatha remain
ep beat ep beat driven revenu upsid
xgeva revenu revenu
includ mileston novarti aimovig estim cost
ahead narrow bottom line impact revenu upsid management
increas total revenu guidanc non-
gaap ep guidanc management announc
head sean harper head commerci toni hooper
transit role dave rees current head translat scienc
oncolog name new head murdo gordon
formerli bristol-my squibb name head commerci
gordon start rees assum role harper
remain period transit
takeaway call management expect sg spend
consist sg spend level management conduct share
repurchas plan conduct addit repurchas
management note freseniu medic current
conduct pilot program parsabiv help determin eventu treatment
protocol util therapi current repres
repatha commerci sale recent negoti increas access
repatha expect result cut payer requir document
util manag um remain requir
physician attest exchang relax um criteria
increas rebat repatha aimovig launch management note
larg bolu patient patient current receiv
free drug rapidli convert patient paid prescript
um criteria aimovig current requir physician attest
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
negoti current underway payer contract place cover
commerci live management report kanjinti herceptin
biosimilar recent launch europ compani depriorit
bcma molecul base earli data bcma bite molecul
indic bite molecul may prove effect
approach kyproli eu revenu benefit one-tim
purchas eu
solid upsid quarter debat stay repres strong quarter
key product ahead consensu management increas top
bottom line guidanc addit aimovig launch earli stage
found management commentari regard patient demand relax um criteria
encourag data readout earli stage pipelin also come
sight phii data antibodi migrain prevent phi
data bcma bite phi data bite
expect flip side expect investor concern regard
recent approv biosimilar neulasta persist maintain consensu
biosimilar competit pipelin contribut drive risk-reward
biosimilar competit
overweight amgen believ
upsid pipelin recent
launch help reduc long-term risk
compani current base busi face
signific inorgan opportun growth
stabl base even biosimilar
believ protect key franchis
biosimilar competit near-term
long-term forecast gradual share
shift biosimilar versu cliff key
product neulasta enbrel
project period
divers pipelin begin
appreci gener posit
late-stag data key compound includ
erenumab migrain biosimilar
portfolio encourag outcom data
also report repatha
believ data drive fundament shift
repatha uptak beyond
launch aimovig erenumab
biosimilar entrant key legaci product
enbrel neulasta enbrel price power
risk achiev price
failur late-stag pipelin
lack margin expans
deriv pt discount cash flow dcf analysi
use wacc termin growth rate post
bear case main revenu driver model
eros base busi due biosimilar launch repatha
matur late-stag pipelin
lower biosimilar impact coupl outsiz revenu phase
pipelin assum pipelin sale romosozumab
biosimilar erenumab repatha sale modest
line penetr kyproli sale enbrel long-
term patent hold biosimliar enter market minim
impact biosimilar expos product biosimilar neulasta take
total neulasta share
us biosimilar impact similar trend europ modest result
phase pipelin assum pipelin sale
biosimilar erenumab repatha sale
line penetr kyproli relapsed/refractori market
global sale enbrel biosimilar begin take share
modest impact biosimilar expos product biosimilar neulasta take
total neulasta share
signific biosimilar impact pipelin contribut except repatha
assum repatha sale line penetr
kyproli relapsed/refractori market sale enbrel
biosimilar enter market take signific share brand
enbrel notabl impact biosimilar expos product biosimilar
neulasta take total neulasta share assum sg
save lt sg sale
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
import us regulatori disclosur subject compani
june benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur amgen inc avrobio inc beigen
within last month receiv compens invest bank servic amgen inc avrobio inc beigen ltd
next month expect receiv intend seek compens invest bank servic
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani amgen inc avrobio inc beigen ltd biogen inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc biogen inc
 co llc make market secur amgen inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
